NTRK Therapy among Different Types of Cancers, Review and Future Perspectives
International Journal of Molecular Sciences · 17.02.2024 · 25 (4) · 2366
DOI: 10.3390/ijms25042366 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 17.02.2024. Verfasst von Nyein Wint Yee Theik und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Internal Medicine, Memorial Healthcare System, Pembroke Pines, FL 33028, USA. Hauptthemen laut MEDLINE: Receptor, trkA, Neoplasms. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Neurotrophic tyrosine receptor kinase (NTRK) has been a remarkable therapeutic target for treating different malignancies, playing an essential role in oncogenic signaling pathways. Groundbreaking trials like NAVIGATE led to the approval of NTRK inhibitors by the Food and Drug Administration (FDA) to treat different malignancies, significantly impacting current oncology treatment. Accurate detection of NTRK gene fusion becomes very important for possible targeted therapy. Various methods to detect NTRK gene fusion have been applied widely based on sensitivity, specificity, and accessibility. The utility of different tests in clinical practice is discussed in this study by providing insights into their effectiveness in targeting patients who may benefit from therapy. Widespread use of NTRK inhibitors in different malignancies could remain limited due to resistance mechanisms that cause challenges to medication efficacy in addition to common side effects of the medications. This review provides a succinct overview of the application of NTRK inhibitors in various types of cancer by emphasizing the critical clinical significance of NTRK fusion gene detection. The discussion also provides a solid foundation for understanding the current challenges and potential changes for improving the efficacy of NTRK inhibitor therapy to treat different malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Internal Medicine, Memorial Healthcare System, Pembroke Pines, FL 33028, USA.
- Memorial Cancer Institute, Memorial Healthcare System, Pembroke Pines, FL 33028, USA.
- Memorial Cancer Institute, Office of Human Research, Florida Atlantic University (FAU), Pembroke Pines, FL 33028, USA.
- Memorial Cancer Institute, Memorial Healthcare System, Florida Atlantic University (FAU), Pembroke Pines, FL 33028, USA.
ORCID-Profile: Meri Muminovic, Andres M Alvarez-Pinzon, Luis E Raez
Zitieren
APA
Theik, N. W. Y., Muminovic, M., Alvarez-Pinzon, A. M., Shoreibah, A., Hussein, A. M., & Raez, L. E. (2024). NTRK Therapy among Different Types of Cancers, Review and Future Perspectives. International Journal of Molecular Sciences, 25(4), 2366. https://doi.org/10.3390/ijms25042366
Vancouver
Theik NWY, Muminovic M, Alvarez-Pinzon AM, Shoreibah A, Hussein AM, Raez LE. NTRK Therapy among Different Types of Cancers, Review and Future Perspectives. International Journal of Molecular Sciences. 2024;25(4):2366. doi:10.3390/ijms25042366
BibTeX
@article{Theik2024,
author = {Theik, Nyein Wint Yee and Muminovic, Meri and Alvarez-Pinzon, Andres M and Shoreibah, Ahmed and Hussein, Atif M and Raez, Luis E},
title = {NTRK Therapy among Different Types of Cancers, Review and Future Perspectives},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {4},
pages = {2366},
doi = {10.3390/ijms25042366}
}
EUVIMED